Quarterly results for Jupiter Life Line Hospitals Ltd

Jupiter Life Line Hospitals Limited
Q1 FY26 Results Announcement – August 1, 2025

Revenue:
Standalone: ₹2,779.42 million, up 15.3% YoY (Q1 FY26 vs Q1 FY25) and 1.5% QoQ.
Consolidated: ₹3,476.25 million, up 20.5% YoY and 6.4% QoQ.
Profitability:
Standalone Net Profit: ₹432.94 million, up 6.5% YoY; Net Profit Margin approx. 15.6%.
Consolidated Net Profit: ₹438.75 million, down 1.6% YoY; Net Profit Margin approx. 12.6%.
Standalone PBT Margin: ~20.9%; Consolidated PBT Margin: ~17.6%.
EPS:
Standalone: ₹6.60 (not annualised), up from ₹6.20 in Q1 FY25.
Consolidated: ₹6.69 (not annualised), down slightly from ₹6.80 in Q1 FY25.
Balance Sheet / Other Financials:
Paid-up equity share capital steady at ₹655.66 million.
No disclosures on debt, cash reserves, or capital expenditure changes.
Segment Performance:
Single reportable segment: Healthcare services in India.
Hotel division contribution below 10%, no separate disclosure.
Management Commentary / Notes:
Results prepared under Ind AS 34 and SEBI regulations; no changes in accounting policies.
Partnership firms’ results included on net profit basis; immaterial impact.
Jupiter Pharmacy converted to private limited company in March 2025; consolidated line-by-line thereafter.
No exceptional items, one-time gains/losses, or significant corporate actions reported this quarter.
Outlook:
No specific guidance or capital expenditure plans disclosed for upcoming periods.
Auditor’s Report:
Unmodified limited review opinion with no qualifications or concerns.

This summary reflects steady revenue growth and stable profitability for Jupiter Life Line Hospitals Limited in Q1 FY26, with consolidated results incorporating subsidiaries and partnership firms. No material changes in accounting or corporate structure were reported during the quarter.

Note: This is an AI generated summary of the results. There may be inaccuracies in the summary. Please refer to the original document before making investment decisions.